MAP2K7 and Miyoshi myopathy: This study (ClinicalTrials.gov NCT02110355) assessed the safety, tolerability, pharmacokinetics (PK), and maximum tolerated dose (MTD) of AMG 232 combined with dabrafenib-trametinib or trametinib alone in patients with MM with or without BRAFV600 mutations, respectively, and without prior treatment with BRAF or MEK inhibitors.